Is Pharma Leveraging the Diagnostic in Targeted Therapy Branding and Communications? | Diaceutics

Is Pharma Leveraging the Diagnostic in Targeted Therapy Branding and Communications?

June 1st, 2016

Mark Reis
Sanna Jousi
Paul J Pfleiderer


Targeted therapy communications present a host of new opportunities and challenges for brand teams. Research has shown that positive diagnostic sentiment among consumers can be leveraged to enhance and optimize targeted therapy communications. But until now no reports have studied the communication styles pharma has used in targeted therapy communications.

This webinar, led by the Bioceutics team, provides an analysis of targeted therapy communications looking at pharma communication styles, positioning and strategies. It draws insight from the Bioceutics Personalized Healthcare Brand Index Surveillance Report, a first of its kind study of targeted therapies in the marketplace.

Listen to this webinar to learn:

  • An analysis of targeted therapy communications looking at communication styles, positioning and strategies
  • The key drivers in taking a particular communications path
  • What’s working and what’s not working
  • Real world examples and learnings

Expert Insights

April 19th, 2018
The CMS National Coverage Decision on NGS
I. Introduction On March 16, 2018, the Centers for Medicare and Medicaid Services (CMS) finalized a National Coverage Determination (NCD) that cove...
January 19th, 2018
What does the EU IVD Regulation mean for companion diagnostics and LDTs?
Dave Smart, PhD, Director at Diaceutics, discusses the introduction of the EU IVD Regulation. While it is considered a necessary step, the Regulati...
View all expert insights

Competitive Benchmarking Reports

March 16th, 2018
PM Readiness Report 2018 Summary
March 14th, 2017
Pharma Readiness for Diagnostic Integration 2017
View all reports

Publications

June 25th, 2019
FLT3 testing in relapsed Acute Myeloid Leukemia setting is becoming increasingly common, but laboratory turnaround times (TAT) may be a barrier to treatment with second generation FLT3 inhibitors
The treatment landscape in AML has developed at an astonishing pace in the last 3 years, with 5 therapies being approved by the FDA. FLT3 inhibitors gilteritinib (Gil) and quizartinib (Quiz) present an unprecedented opportunity for improved surviv...
May 23rd, 2019
Diaceutics reviews the ongoing debate on diagnostics reform legislation
Thought leaders at Diaceutics recently authored a peer-reviewed article that covers the ongoing national debate over diagnostics reform legislation in the United States. The article is now available online ahead of print in the Journal of Molecula...
View all publications